B
RVNC

Baird’s Revance Therapeutics, Inc. RVNC Stock Holding History

Baird’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		$713K Buy
34,382
+1,550
+5% +$26.8K 0.01% 850
2014
Q4 		$556K Sell
32,832
-3,246
-9% -$56.7K 0.01% 900
2014
Q3 		$697K Buy
+36,078
New +$940K 0.01% 756

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NHG
NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baird's RVNC Position: Q1 2015 in Review

Baird increased its Revance Therapeutics, Inc. (RVNC) stake by 4.7% in Q1 2015, buying an estimated $26.8K and bringing the position to 34,382 shares worth $713K. The position accounts for 0.01% of the portfolio, ranked #850.

Baird first reported a position in RVNC in Q3 2014 and has held it in 3 quarters since. 70 funds tracked by Wall St. Rank hold RVNC as of Q1 2015.

  • Baird held 34,382 shares of Revance Therapeutics, Inc. worth $713K as of Q1 2015.
  • Baird bought 1,550 Revance Therapeutics, Inc. shares in Q1 2015, an estimated $26.8K.
  • Revance Therapeutics, Inc. made up 0.01% of Baird's portfolio in Q1 2015, its #850 holding.
  • Baird first reported a position in Revance Therapeutics, Inc. in Q3 2014 and has held it in 3 quarters since.
  • 70 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2015.

Based on Baird's 13F filing for Q1 2015, filed 13 May 2015.